Bigger, fewer, tougher: the new era of China-US biotech partnerships

▤ Summary

China-US biotech partnering is becoming more complex as US investment and technology controls tighten. Western drug makers still want access to Chinese innovation and will keep pursuing cross-border deals. The article says out-licensing activity from Chinese biotech firms could reach a much larger scale this year. These transactions appear increasingly concentrated among the largest pharmaceutical companies because they have the resources to handle political and regulatory risk.

▦ Linked Companies